Thomas Helleday
- Oncology top 0.05%
- PARP inhibition in cancer therapy 58
- Cancer-related Molecular Pathways 27
- Cancer Research top 0.2%
- Carcinogens and Genotoxicity Assessment 28
- Molecular Biology top 0.1%
- DNA Repair Mechanisms 163
- CRISPR and Genetic Engineering 37
- Cancer therapeutics and mechanisms 28
- Biochemical and Molecular Research 20
- Cell Biology top 0.5%
- Microtubule and mitosis dynamics 25
- Genetics top 0.5%
- Co-authors
- Niklas SchultzEva PetermannHelen E. BryantCecilia LundinMark MeuthHuw D. ThomasNicola J. CurtinSuzanne Kyle
- Partner nations
- SwedenUnited KingdomUnited States
In The Last Decade
Thomas Helleday
263 papers receiving 21.8k citations
Hit Papers
Peers
Comparison fields: 5 of 154
- Oncology 10.2k
- Cancer Research 4.0k
- Molecular Biology 17.8k
- Cell Biology 1.6k
- Genetics 2.2k
Countries citing papers authored by Thomas Helleday
This map shows the geographic impact of Thomas Helleday's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Thomas Helleday with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Thomas Helleday more than expected).
Fields of papers citing papers by Thomas Helleday
This network shows the impact of papers produced by Thomas Helleday. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Thomas Helleday. The network helps show where Thomas Helleday may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Thomas Helleday, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2023 | 1 | |
| 2 | 2022 | 8 | |
| 3 | 2021 | 20 | |
| 4 | 2020 | 21 | |
| 5 | 2018 | 32 | |
| 6 | 2017 | 31 | |
| 7 | 2016 | 71 | |
| 8 | 2016 | 35 | |
| 9 | 2015 | 68 | |
| 10 | 2013 | 51 | |
| 11 | 2012 | 273 | |
| 12 | 2012 | 73 | |
| 13 | 2012 | 24 | |
| 14 | 2011 | 4 | |
| 15 | 2011 | 106 | |
| 16 | 2010 | 100 | |
| 17 | 2010 | 221 | |
| 18 | 2010 | 176 | |
| 19 | 2010 | 138 | |
| 20 | 2010 | 80 |
About Thomas Helleday
Thomas Helleday is a scholar working on Oncology, Cancer Research and Molecular Biology, having authored 264 papers that have together received 22.1k indexed citations. Recurring topics across this work include DNA Repair Mechanisms (163 papers), PARP inhibition in cancer therapy (58 papers), CRISPR and Genetic Engineering (37 papers), Carcinogens and Genotoxicity Assessment (28 papers), Cancer therapeutics and mechanisms (28 papers), Cancer-related Molecular Pathways (27 papers), Microtubule and mitosis dynamics (25 papers) and Biochemical and Molecular Research (20 papers). The work is most often cited by research in Oncology (10.2k citations), Cancer Research (4.0k citations) and Molecular Biology (17.8k citations). Thomas Helleday has collaborated with scholars based in Sweden, United Kingdom and United States. Frequent co-authors include Niklas Schultz, Eva Petermann, Helen E. Bryant, Cecilia Lundin, Mark Meuth, Huw D. Thomas, Nicola J. Curtin, Suzanne Kyle, Elena López‐Knowles and Ricky A. Sharma. Their work appears in journals such as Nucleic Acids Research, Cancer Research, DNA repair, Journal of Molecular Biology and Journal of Biological Chemistry.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.